Raymond James Financial Services Advisors’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $27.5M | Sell |
52,801
-17,650
| -25% | -$9.43M | 0.04% | 431 |
|
|
2024
Q2 | $38.2M | Buy |
70,451
+1,409
| +2% | +$745K | 0.05% | 321 |
|
|
2024
Q1 | $35.8M | Sell |
69,042
-6,783
| -9% | -$3.37M | 0.05% | 334 |
|
|
2023
Q4 | $35.8M | Buy |
75,825
+5,954
| +9% | +$2.75M | 0.06% | 310 |
|
|
2023
Q3 | $30.4M | Buy |
69,871
+12,967
| +23% | +$5.88M | 0.06% | 319 |
|
|
2023
Q2 | $25.3M | Buy |
56,904
+5,861
| +11% | +$2.7M | 0.04% | 389 |
|
|
2023
Q1 | $23.5M | Buy |
51,043
+1,993
| +4% | +$948K | 0.04% | 395 |
|
|
2022
Q4 | $25.2M | Buy |
49,050
+191
| +0.4% | +$97K | 0.05% | 363 |
|
|
2022
Q3 | $22.2M | Sell |
48,859
-1,972
| -4% | -$944K | 0.05% | 364 |
|
|
2022
Q2 | $24.5M | Sell |
50,831
-267
| -0.5% | -$132K | 0.05% | 351 |
|
|
2022
Q1 | $25.1M | Buy |
51,098
+959
| +2% | +$438K | 0.05% | 377 |
|
|
2021
Q4 | $23.2M | Buy |
50,139
+6,101
| +14% | +$2.57M | 0.04% | 400 |
|
|
2021
Q3 | $16.4M | Buy |
44,038
+1,557
| +4% | +$592K | 0.03% | 500 |
|
|
2021
Q2 | $16.2M | Buy |
42,481
+1,447
| +4% | +$553K | 0.03% | 506 |
|
|
2021
Q1 | $14.7M | Buy |
41,034
+6,678
| +19% | +$2.15M | 0.03% | 481 |
|
|
2020
Q4 | $11M | Buy |
34,356
+77
| +0.2% | +$23.6K | 0.03% | 521 |
|
|
2020
Q3 | $9.21M | Buy |
34,279
+197
| +0.6% | +$53K | 0.03% | 531 |
|
|
2020
Q2 | $8.97M | Buy |
34,082
+655
| +2% | +$175K | 0.03% | 492 |
|
|
2020
Q1 | $7.59M | Sell |
33,427
-1,004
| -3% | -$274K | 0.03% | 438 |
|
|
2019
Q4 | $10.4M | Buy |
34,431
+4,601
| +15% | +$1.27M | 0.03% | 494 |
|
|
2019
Q3 | $7.16M | Buy |
29,830
+4,508
| +18% | +$1.24M | 0.03% | 566 |
|
|
2019
Q2 | $7.15M | Sell |
25,322
-7,347
| -22% | -$2.01M | 0.03% | 548 |
|
|
2019
Q1 | $9.38M | Buy |
32,669
+16,448
| +101% | +$4.76M | 0.04% | 444 |
|
|
2018
Q4 | $4.26M | Buy |
16,221
+3,299
| +26% | +$907K | 0.02% | 593 |
|
|
2018
Q3 | $3.54M | Sell |
12,922
-450
| -3% | -$117K | 0.02% | 784 |
|
|
2018
Q2 | $3.18M | Buy |
13,372
+3,122
| +30% | +$723K | 0.02% | 791 |
|
|
2018
Q1 | $2.25M | Buy |
10,250
+2,510
| +32% | +$590K | 0.01% | 876 |
|
|
2017
Q4 | $1.74M | Sell |
7,740
-1,766
| -19% | -$376K | 0.01% | 979 |
|
|
2017
Q3 | $1.8M | Buy |
9,506
+1,997
| +27% | +$380K | 0.01% | 968 |
|
|
2017
Q2 | $1.41M | Buy |
7,509
+735
| +11% | +$132K | 0.01% | 1051 |
|
|
2017
Q1 | $1.12M | Buy |
6,774
+978
| +17% | +$156K | 0.01% | 1108 |
|
|
2016
Q4 | $833K | Sell |
5,796
-857
| -13% | -$115K | 0.01% | 1221 |
|
|
2016
Q3 | $834K | Sell |
6,653
-197
| -3% | -$25.4K | 0.01% | 1192 |
|
|
2016
Q2 | $900K | Buy |
6,850
+328
| +5% | +$44.9K | 0.01% | 1099 |
|
|
2016
Q1 | $906K | Buy |
+6,522
| New | +$872K | 0.01% | 946 |
|
Other funds holding ELV
Raymond James Financial Services Advisors's ELV Position: Q3 2024 in Review
Raymond James Financial Services Advisors reduced its Elevance Health (ELV) stake by 25% in Q3 2024, selling an estimated $9.43M and leaving 52,801 shares worth $27.5M. The position accounts for 0.04% of the portfolio, ranked #431.
Raymond James Financial Services Advisors first reported a position in ELV in Q1 2016 and has held it in 35 quarters since. The position peaked at $38.2M in Q2 2024. 1,694 funds tracked by Wall St. Rank hold ELV as of Q3 2024.
- Raymond James Financial Services Advisors held 52,801 shares of Elevance Health worth $27.5M as of Q3 2024.
- Raymond James Financial Services Advisors sold 17,650 Elevance Health shares in Q3 2024, an estimated $9.43M.
- Elevance Health made up 0.04% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #431 holding.
- Raymond James Financial Services Advisors first reported a position in Elevance Health in Q1 2016 and has held it in 35 quarters since.
- Raymond James Financial Services Advisors's Elevance Health position peaked at $38.2M in Q2 2024.
- 1,694 funds tracked by Wall St. Rank held Elevance Health as of Q3 2024.
Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.